Cancer Genetics — Q2 2016 Earnings Presentation
14 slides from Cancer Genetics's earnings presentation, Aug 10, 2016
Slide 1: Q2 2016 Earnings Call
August 10, 2016 Q2 2016 Earnings Call Nasdaq (CGIX) THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE
Slide 2: Forward-Looking Statements
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Forward-Looking Statements 2 These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future gro
Slide 3: Everything we do at CGI is focused on one key idea
EVERYTHING WE DO AT CGI IS FOCUSED ON ONE KEY IDEA… …DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN ONCOLOGY DIAGNOSTICS & PRECISION MEDICINE
Slide 4: Investor Highlights: Cancer Genetics Addresses the Trends in Oncology
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma CONTRACTS WITH 8 of 1
Slide 5: 2nd Quarter 2016 Revenue Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call 2nd Quarter 2016 Revenue Highlights 67% REVENUE GROWTHFROM Q2 2015 Q2 TOTAL REVENUE GREW FROM $4.2M TO 2015 2016 $1.5 $4.2 $7.0 $0 $4 $7 3-Year CAGR 67.1% Q 2 201 4 Q 2 201 5 Q 2 201 6 5
Slide 6: Revenues By Category
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Revenues By Category 6 BIOPHARMA SERVICES CLINICAL SERVICES DISCOVERY SERVICES 64% 30% 6% Q2 2015 $4.2 Mn 206% increase in clinical test volume over Q2 2015 due to enhanced portfolio in both immuno-oncology testing and our solid tumor ce
Slide 7: Q2 2016 Revenue Trends & Drivers
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Q2 2016 Revenue Trends & Drivers 7 Negotiated and executed over 50 new contracts and project extensions for biopharma testing throughout CGI. $6+ million in biopharma contracts closed during Q1 2016; contracts will deliver future reven
Slide 8: Q2 2016 Corporate Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Q2 2016 Corporate Highlights 8 Launched a proprietary comprehensive next-generation sequencing panel FOCUS::Lymphoma™ with CLIA validation to apply in both clinical care and trials by biotech and pharmaceutical companies. FOCUS::CLL™ b
Slide 9: Q2 2016 Collaboration Highlights
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Q2 2016 Collaboration Highlights 9 Biopharmaceutical company, H3 Biomedicine Inc. (H3), selected CGI to provide clinical biomarker services for H3’s lead oncology drug candidate H3B-8800, an anticancer therapeutic agent being developed f
Slide 10: Our Three Pillars of Innovation
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Our Three Pillars of Innovation I. UNIQUE CONTENT VIA PARTNERSHIPS & COLLABORATIONS II. IMMUNO-ONCOLOGY CAPABILITIES THAT ARE INDUSTRY LEADING III. LIQUID BIOPSY HIGH SENSITIVITY CELL-FREE ANALYSIS • Mayo Clinic Oncospire Genomics joint ve
Slide 11: Summary Statement of Operations
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call Summary Statement of Operations 11 Income Statement Item ($ in Thousands) Q2 2015 Q1 2016 Q2 2016 Revenue $4,185 $6,068 $7,000 Gross Profit 1,088 1,965 2,716 Gross Margin (%) 26% 32% 39% Research & Development (R&D) 1,256 1,532 1,680 Sales
Slide 12: Q2 2016 Financial Highlights: Revenue
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call 12 Revenues were $7.0 million, a 67% increase over Q2 2015 revenues of $4.2 million, and 15% sequential growth over Q1 2016. Revenue from Biopharma Services grew 26% and Clinical Services increased by 4% sequentially over Q1 2016. Gr
Slide 13: Q2 2016 Financial Highlights: Expenses
Cancer Genetics, Inc. | NASDAQ: CGIX | Q2 2016 Earnings Call 13 Expenses for the quarter were $11.0 million, a 2.2% improvement over Q1 2016 expenses of $11.3 million. COGS was $4.3 million, a modest 4% increase over Q1 2016 while revenue grew 15%. G&A expenses were $3.7 million, a 15% improve
Slide 14: The Oncology Diagnostics Partner from Bench to Bedside
THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax